Investment analysts at StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB – Get Free Report) in a report issued on Monday. The firm set a “sell” rating on the stock.
Navidea Biopharmaceuticals Price Performance
Shares of NYSE NAVB opened at $0.04 on Monday. Navidea Biopharmaceuticals has a 12-month low of $0.02 and a 12-month high of $0.27. The firm’s 50-day simple moving average is $0.04 and its 200 day simple moving average is $0.05. The company has a market cap of $3.50 million, a price-to-earnings ratio of -0.58 and a beta of 1.13.
Navidea Biopharmaceuticals Company Profile
Featured Articles
- Five stocks we like better than Navidea Biopharmaceuticals
- 5 Top Rated Dividend Stocks to Consider
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Insider Trading – What You Need to Know
- Hilton Demonstrates Asset Light is Right for Investors
- How Can Investors Benefit From After-Hours Trading
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.